Persistent disease burden despite advanced therapies in inflammatory bowel disease: a real-world patient-reported survey from Greece
Clinical Scorecard: Ongoing Impact of Inflammatory Bowel Disease Despite Modern Treatments: Insights from a Patient-Reported Survey in Greece
At a Glance
| Category | Detail |
|---|
| Condition | Inflammatory Bowel Disease (IBD) |
| Key Mechanisms | Immune-mediated inflammation of the gastrointestinal tract |
| Target Population | Adults with Crohn’s disease (CD) and ulcerative colitis (UC) receiving advanced therapies |
| Care Setting | Patient-reported outcomes in clinical practice |
Key Highlights
- 57.1% of patients reported active disease despite advanced therapies
- 76.4% experienced impaired quality of life (QoL)
- 30.3% reported work productivity loss
- 39.1% expressed dissatisfaction with their advanced therapy
- 10.9% reported reduced adherence to treatment
Guideline-Based Recommendations
Diagnosis
- Use validated questionnaires to assess disease activity and patient-reported outcomes
Management
- Consider advanced therapies including biologics and small-molecule drugs
Monitoring & Follow-up
- Regularly assess quality of life, work productivity, and depressive symptoms
Risks
- Monitor for treatment-related toxicity and dissatisfaction with treatment response
Patient & Prescribing Data
287 patients with IBD (201 with CD, 86 with UC)
Less than half of patients remain on their initial biologic therapy after one year
Clinical Best Practices
- Integrate patient-reported outcomes into disease assessment
- Address communication gaps regarding QoL and psychosocial concerns
- Evaluate and adjust treatment strategies based on patient feedback
Related Resources & Content
